Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NurOwn Phase 2a in ALS
NCT01777646Phase 2Completed
- Sponsor
- BrainStorm Cell Therapeutics Inc.
- Start
- Dec 2012
- Primary completion
- Sep 2014
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of MSC-NTF in amyotrophic lateral sclerosis (ALS), sponsored by BrainStorm Cell Therapeutics Inc.. Started Dec 2012; status: completed.
02
Drugs
MSC-NTF
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT01777646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01777646.